首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation
【24h】

Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation

机译:具有高CD3(+)细胞计数的脐带血单位可预测体内T细胞贫乏的单脐带血移植后的早期淋巴细胞恢复

获取原文
获取原文并翻译 | 示例
       

摘要

Although high absolute lymphocyte count (ALC) early after transplantation is a simple surrogate for immune reconstitution, few studies to date have established the predictive factors for ALC after umbilical cord blood transplantation (UCBT). We retrospectively studied the factors associated with early lymphocyte recovery and the impact of the ALC on day +42 (ALC42) of >= 300 x 10(6)/L on outcomes in 210 consecutive pediatric and adult patients (112 males; median age, 15 years; range, 0.3 to 60 years; interquartile range, 4 to 36 years) who underwent myeloablative in vivo T cell-depleted single UCBT between 2005 and 2014 for malignant and nonmalignant disorders. In a logistic multivariate regression model, factors favoring a higher ALC42 were higher infused CD3(+) cell dose (odds ratio [OR], 2.7; 95% CI, 1.4 to 5.2; P = .004), lower antithymocyte globulin dose (OR; 2.3; 95% CI, 1.2 to 4.5; P = .01), and better HIA match (OR, 2.1; 95% CI, 1.1 to 4.1; P = .03). In multivariate analysis, lower ALC42 was associated with higher nonrelapse mortality (hazard ratio [HR], 1.76; 95% CI, 1.34 to 2.32; P = .001), whereas a higher ALC42 was associated with better disease-free survival (HR, 2.03; 95% CI, 1.15 to 3.6; P < .001) and overall survival (HR, 2.03; 95% CI, 1.17 to 3.6; P < .001). Our study suggests that the selection of better HLA-matched cord blood units containing higher CD3+ cell counts and the use of conditioning regimens with lower ATG doses could improve immune reconstitution after UCBT. (C) 2016 American Society for Blood and Marrow Transplantation.
机译:尽管移植后早期的绝对淋巴细胞计数高(ALC)是免疫重建的简单替代方法,但迄今为止,很少有研究确定脐带血移植(UCBT)后ALC的预测因素。我们回顾性研究了210例连续的儿科和成年患者(112名男性;中位年龄; 15岁;范围0.3到60岁;四分位间距:4到36岁)于2005年至2014年间因恶性和非恶性疾病接受了骨髓消融的体内T细胞缺失单个UCBT。在逻辑多元回归模型中,支持较高ALC42的因素包括较高的注入CD3(+)细胞剂量(优势比[OR],2.7; 95%CI,1.4至5.2; P = .004),抗胸腺细胞球蛋白剂量较低(OR ; 2.3; 95%CI,1.2至4.5; P = 0.01),以及更好的HIA匹配(OR,2.1; 95%CI,1.1至4.1; P = .03)。在多变量分析中,较低的ALC42与较高的非复发死亡率相关(危险比[HR]为1.76; 95%CI为1.34至2.32; P = .001),而较高的ALC42与无病生存期更好(HR, 2.03; 95%CI,1.15至3.6; P <.001)和总体生存率(HR,2.03; 95%CI,1.17至3.6; P <.001)。我们的研究表明,选择更好的HLA匹配脐带血单位包含更高的CD3 +细胞数量,并使用较低ATG剂量的调理方案可以改善UCBT后的免疫重建。 (C)2016美国血液和骨髓移植学会。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号